Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Dexamethasone

Bortezomib

Pomalidomide

Dexamethasone acetate

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

mezigdomide

BMS Study Connect Contact Center www.BMSStudyConnect.com

First line of the email MUST contain the NCT# and Site #.

Site 0366

Site 0272

James Berenson, Site 0273

Sumit Sawhney, Site 0303

PETROS NIKOLINAKOS, Site 0211

Audrik Perez Rodriguez, Site 0330

Al-Ola Abdallah, Site 0080

Site 0358

Hana Safah, Site 0255

Site 0357

Site 0246

Matthew Pianko, Site 0271

John Hrom, Site 0088

Bruno Fang, Site 0288

Site 0363

Shashank Cingam, Site 0302

Maria Nieto, Site 0257

Saad Jamshed, Site 0108

Cristina Gasparetto, Site 0260

Faiz Anwer, Site 0076

Site 0359

Jason Chandler, Site 0223

Robert Orlowski, Site 0275

Matthew Butler, Site 0267

Stephan Kendall, Site 0207

Christopher Vaughn, Site 0297

Nicholas Burwick, Site 0268

Maximiliano Romero, Site 0318

Gaston Caeiro, Site 0249

Ruben Kowalyszyn, Site 0239

CARINA GUMPEL, Site 0200

Hugo Ferro, Site 0213

Claudia Shanley, Site 0214

gonzalo granero, Site 0248

Silvia Ling, Site 0055

Wojt Janowski, Site 0004

Gurdeep Parmar, Site 0017

Craig Wallington-Gates, Site 0327

Olga Motorna, Site 0221

Andrew Spencer, Site 0003

Hang Quach, Site 0002

Bradley Augustson, Site 0040

Thomas Spanberger, Site 0012

Klaus Podar, Site 0008

Laurenz Schöffmann, Site 0024

Petra Pichler, Site 0011

Michael Fillitz, Site 0025

Natalie Put, Site 0138

Nicolas Kint, Site 0206

Isabelle Vande Broek, Site 0179

Ka Lung Wu, Site 0136

Edvan Crusoe, Site 0046

Marcelo Capra, Site 0044

Marcelo Lacerda, Site 0314

Ederson Mattos, Site 0305

Angelo Maiolino, Site 0049

Vania Hungria, Site 0050

Nelson Hamerschlak, Site 0045

Sabrina Trudel, Site 0225

Jean Samuel Boudreault-Pedneault, Site 0174

Marc Lalancette, Site 0222

Alejandro Berkovits, Site 0329

Christine Rojas Hopkins, Site 0332

Wenming Chen, Site 0062

Zhongxia Huang, Site 0165

Yujun Dong, Site 0150

Hongbin Zhang, Site 0144

Zhifeng Li, Site 0237

Baijun Fang, Site 0117

Zhongjun XIA, Site 0177

Site 0238

Jun Luo, Site 0240

qingchi Liu, Site 0254

zunmin zhu, Site 0113

Chunyan Sun, Site 0142

yanjuan He, Site 0155

Jing Liu, Site 0147

Site 0111

xin zhou, Site 0139

Aijun Liao, Site 0287

Aili He, Site 0148

Wei Wang, Site 0169

Chunkang Chang, Site 0114

Site 0350

Weihua Zhang, Site 0164

Site 0356

Yafei Wang, Site 0119

Site 0353

MINGXIA SHI, Site 0202

Bristol-Myers Squibb

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

OR is defined as the number of participants who achieve best response of partial response (PR) or better according to the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma

Defined as the number of participants who achieve best response of complete response (CR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

Defined as the number of participants who achieve best response of very good partial response (VGPR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

Defined as the number of participants who achieve complete response (CR) or better and MRD negative (defined at a sensitivity of a minimum of 1 in 105 nucleated cells)

The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

Celgene

Spots Global Cancer Trial Database for mezivd

Every month we try and update this database with for mezivd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mezivd

Every month we try and update this database with for mezivd cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mezivd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.